ERBB2 and aneurysmal bone cyst: Rugo and colleagues conducted the SOPHIA trial, a multinational, open‐label, randomized phase 3 study to compare the clinical effectiveness of margetuximab versus trastuzumab in patients with HER2‐positive ABC after progression on two or more lines of HER2‐directed therapies and at least one non‐hormonal therapy for metastatic cancer.